metabolic diseases

News

Zealand forges obesity alliance with AI specialist Generate

Zealand has added another strand to its programme of weight-loss drug development, linking with AI player Generate on multispecific protein therapies.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Patients

Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

News

Roche breaks ground on US manufacturing facility

Roche's Genentech unit has started work on a $700m manufacturing facility in North Carolina, part of a promised $50bn US investment programme.

News

Lilly trumpets heart health data with Mounjaro

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

News

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

Zealand forges obesity alliance with AI specialist Generate

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Rewriting the MASLD playbook

Roche breaks ground on US manufacturing facility

Lilly trumpets heart health data with Mounjaro

Novo makes fresh obesity play with $2.2bn Septerna deal

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

metabolic diseases

Editor's Picks